Cancer immunotherapy has emerged as a powerful treatment option characterized by durable remissions and tolerable side effects.
In recent years, an unprecedented number of immune-based therapeutic modalities have been approved in the first- and second-line as well as in the adjuvant setting across a growing number of malignancies. This influx of approvals has created a need to stay current on the latest recommendations for the appropriate application of immunotherapy.
SITC Cancer Immunotherapy CONNECT is your hub to participate in live and online educational opportunities to learn more about integrating cancer immunotherapy into your practice. Download a variety of resources in the SITC Resource Library and connect with other clinicians in the Cancer Immunotherapy CONNECT Open Forum to learn more about the latest approvals, patient selection criteria, relevant biomarkers and immune-related adverse events.
Submission Period Closes: Tuesday, February 20, 2018 at 5 p.m. EST
*Must be a SITC member to apply.
The majority of NSCLC patients do not still respond to PD-1/PD-L1 treatment. Chemotherapy is theorized to increase the release of tumor antigen resulting in increased response with immunotherapy. ...
more details in our latest news story: bit.ly/2CpnCWQ ------------------------------ Jade Parker Editor Future Science Group ------------------------------
Course Name: 6 th Annual Lung Cancer Symposium
Course Date: Friday, March 2, 2018
Course Co-Directors and Planners : Ralph Zinner, MD; Gregory Kane, MD; Judith Alberto, RPh; Rita ...
This message was posted by a user wishing to remain anonymous Hi All His is an attempt to find answers on the observed onset of effect on Opdivo / Nivolumab treatment. If you are a doctor ...
View More Clinician Resources
In this video, hear SITC Annual Meeting delegates explain the purpose and benefits for joining thousands of their colleagues at the Annual Meeting & Pre-Conference Programs, share how far the science of cancer immunotherapy has progressed and predict where the field is headed. Also, learn about the benefits of becoming a member of SITC.
For more than 30 years SITC (Society for Immunotherapy of Cancer) has been fighting for treatment and a cure for cancer through research and collaboration. SITC members all over the world are leading the charge against cancer. We’re traveling the globe to meet these thought leaders and demonstrate the crucial work that they’re doing to impact advances in both the science and clinical application of immunotherapy.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com